Is it time to go orphan?
Over the years, numerous of investigations and articles have analyzed the likelihood of a drug’s approval per each phase of the clinical development. Latest in line is Endpoints news concluding that the statistics haven’t changed much over the years – with one exception: the likelihood of success for Phase 3 trials has increased. But why is that and what difference does it make to an investor? …
May 31, 2019
Our success depends on how well our clients perform. We are here to equip them with the right tools and empower them with the right insight, so they confidently can strike deals, partnerships and attract investments.
We understand the business issues facing smaller biotech companies and share a passion with our clients to drive the future of medicine.
We support leaders with actionable recommendations and insights with a fervor and razor-sharp focus. Our approach is doing so by creating tailored solutions to challenging business issues and crafting strategies to achieve business goals and brand visibility. Whether it is business development, asset valuation or communication, we are a reliable partner that always walk that extra mile.